EIF4A1 and colorectal carcinoma: Moreover, Elevated eukaryotic translation initiation factor 4A (EIF4A) in CRC patients was associated with poorer survival rate, poor response to oxaliplatin and more distant metastasis.188 The EIF4A inhibitor silvestrol and oxaliplatin have a synergistic effect, and the combined use of the two may represent a new treatment strategy for patients with CRLM.